Bispecific Antibodies in Lymphoma — Another Win for T Cells
Mené sur 155 patients atteints d'un lymphome diffus à grandes cellules B, réfractaire ou récidivant (durée médiane de suivi : 12,6 mois), cet essai de phase I/II évalue l'efficacité, du point de vue du taux de réponse complète, et la toxicité du glofitamab (un anticorps bispécifique ciblant le récepteur CD20 des cellules B et le récepteur CD3 des lymphocytes T), après l'échec d'au moins deux lignes thérapeutiques
Harnessing the power of a patient’s own T cells has revolutionized the treatment of many cancers, including lymphoma. The most broadly applicable T-cell–directed therapies are the programmed death 1 (PD-1) inhibitors, a remarkably effective wake-up call for T cells that have been lulled to sleep by cancer cells. Although PD-1 inhibitors have improved outcomes in Hodgkin’s lymphoma, they are inactive in most non-Hodgkin’s lymphomas. An alternative T-cell strategy — chimeric antigen receptor (CAR) T cells, which are autologous T cells genetically engineered to target B-cell antigens — has shown promise in multiple subtypes of B-cell lymphoma. Mature data on CAR . . .
New England Journal of Medicine , éditorial, 2021